Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

NCT04678739 is registered in ClinicalTrials.gov with M Abdur Rahim Medical College and Hospital as lead sponsor.

NCT NCT04678739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04678739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
Lead sponsor
M Abdur Rahim Medical College and Hospital
Phase
Phase 3
Overall status
Completed
Start date
August 15, 2020
Completion date
February 10, 2021
Enrollment
205 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 ards, covid19